

Aze Wilson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/750268/publications.pdf>

Version: 2024-02-01

12
papers

122
citations

1683354

5
h-index

1719596

7
g-index

12
all docs

12
docs citations

12
times ranked

89
citing authors

#	ARTICLE	IF	CITATIONS
1	A Comparative Analysis of Drug Therapy, Disease Phenotype, and Health Care Outcomes for Men and Women with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4287-4294.	1.1	6
2	High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor \pm antagonists. <i>Scientific Reports</i> , 2022, 12, 1185.	1.6	22
3	Correspondence: Failure to Achieve Target Drug Concentrations During Induction and Not HLA-DQA1*05 Carriage is Associated with Anti-Drug Antibody Formation in Patients with Inflammatory Bowel Disease – Is HLA-DQA1*05 gone before it’s here?. <i>Gastroenterology</i> , 2022, , .	0.6	0
4	A More Severe Non-melanoma Skin Cancer Phenotype Is Seen in Patients with Inflammatory Bowel Disease on Tumor Necrosis Factor- \pm Antagonists. <i>Digestive Diseases and Sciences</i> , 2021, 66, 4436-4440.	1.1	0
5	High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study. <i>BMC Gastroenterology</i> , 2021, 21, 77.	0.8	13
6	High quantities: Evaluating the association between cannabis use and propofol anesthesia during endoscopy. <i>PLoS ONE</i> , 2021, 16, e0248062.	1.1	9
7	Low Serum Tumor Necrosis Factor- \pm Antagonist Concentrations in Patients With Inflammatory Bowel Disease Who Achieve Healing From Pyoderma Gangrenosum. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e141-e143.	0.9	0
8	Letter: genetic variation in the <i>HLA-DQA1*05</i> allele predicts tumour necrosis factor \pm antagonist immunogenicity – does location matter?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1055-1056.	1.9	1
9	<i>HLA-DQA1*05</i> genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 356-363.	1.9	60
10	Genetic variation in the farnesoid X-receptor predicts Crohn’s disease severity in female patients. <i>Scientific Reports</i> , 2020, 10, 11725.	1.6	8
11	Infliximab treatment for large, multifocal, abdominal pyoderma gangrenosum associated with ulcerative colitis: A case report. <i>SAGE Open Medical Case Reports</i> , 2020, 8, 2050313X2096411.	0.2	3
12	Letter: immunogenicity of infliximab – ready for routine prediction? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 813-814.	1.9	0